These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 731251)
61. Comparison of multifocal visual evoked potential, standard automated perimetry and optical coherence tomography in assessing visual pathway in multiple sclerosis patients. Laron M; Cheng H; Zhang B; Schiffman JS; Tang RA; Frishman LJ Mult Scler; 2010 Apr; 16(4):412-26. PubMed ID: 20207786 [TBL] [Abstract][Full Text] [Related]
62. Visual field analyser: assessment of delay and temporal resolution of vision. Regan D; Varney P; Purdy J; Kraty N Med Biol Eng; 1976 Jan; 14(1):8-14. PubMed ID: 1256098 [No Abstract] [Full Text] [Related]
63. Interocular Differences in Spatial Frequency Influence the Pulfrich Effect. Min SH; Reynaud A; Hess RF Vision (Basel); 2020 Mar; 4(1):. PubMed ID: 32244910 [TBL] [Abstract][Full Text] [Related]
64. A comparison of flight of colours with visually evoked responses in patients with multiple sclerosis. Swart S; Millac P J Neurol Neurosurg Psychiatry; 1980 Jun; 43(6):550-1. PubMed ID: 7205299 [TBL] [Abstract][Full Text] [Related]
66. An unusual presentation of optic neuritis and the Pulfrich phenomenon. O'Doherty M; Flitcroft I BMJ Case Rep; 2009; 2009():. PubMed ID: 21686703 [TBL] [Abstract][Full Text] [Related]
67. The role of myo-inositol in multiple sclerosis. Young GB; Hader WJ; Hiscock M; Warren KG; Logan D J Neurol Neurosurg Psychiatry; 1986 Mar; 49(3):265-72. PubMed ID: 3007676 [TBL] [Abstract][Full Text] [Related]
70. The Pulfrich phenomenon and its alleviation with a neutral density filter. Heron G; Dutton GN Br J Ophthalmol; 1989 Dec; 73(12):1004-8. PubMed ID: 2611182 [TBL] [Abstract][Full Text] [Related]
71. The human magno and parvo systems and selective impairments of their functions. Murav'eva SV; Deshkovich AA; Shelepin YE Neurosci Behav Physiol; 2009 Jul; 39(6):535-43. PubMed ID: 19513851 [TBL] [Abstract][Full Text] [Related]
72. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis. Brown JR; Beebe GW; Kurtzke JF; Loewenson RB; Silberberg DH; Tourtellotte WW Neurology; 1979 Sep; 29(9 pt. 2):3-23. PubMed ID: 381971 [TBL] [Abstract][Full Text] [Related]
73. The Pulfrich solidity illusion: a surprising demonstration of the visual system's tolerance of solidity violations. Bai D; Strickland B Psychon Bull Rev; 2023 Oct; 30(5):1782-1787. PubMed ID: 36964479 [TBL] [Abstract][Full Text] [Related]
74. Diagnostic uses of the Pulfrich phenomenon. Frisen L; Hoyt WF; Bird AC; Weale RA Lancet; 1973 Aug; 2(7825):385-6. PubMed ID: 4124567 [No Abstract] [Full Text] [Related]
75. Disturbed "flight of colours" in multiple sclerosis. Mourik J; van Donselaar CA; Minderhoud JM Lancet; 1978 Jan; 1(8055):108. PubMed ID: 74559 [No Abstract] [Full Text] [Related]
76. Contrast sensitivity function for vision testing in suspected demyelinating disease. Pace R; Woo GC Lancet; 1984 Feb; 1(8373):405-6. PubMed ID: 6141475 [No Abstract] [Full Text] [Related]
77. Evidence for the latency-time explanation of the Pulfrich phenomenon. Kolehmainen K; Keskinen E Scand J Psychol; 1974; 15(4):320-1. PubMed ID: 4453825 [No Abstract] [Full Text] [Related]
78. Simultaneous brightness contrast and the Pulfrich phenomenon. DIAMOND AL J Opt Soc Am; 1958 Dec; 48(12):887-90. PubMed ID: 13599079 [No Abstract] [Full Text] [Related]
79. The magnitude of the Pulfrich stereophenomenon as a function of target velocity. LIT A J Exp Psychol; 1960 Mar; 59():165-75. PubMed ID: 14417505 [No Abstract] [Full Text] [Related]
80. New observation of the Pulfrich effect. KATZ MS; SCHWARTZ I J Opt Soc Am; 1955 Jul; 45(7):523-4. PubMed ID: 14381951 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]